Enlight Biosciences, a Boston-based maker of drug discovery and development technologies, said today it has formed a new company called Entrega, which focuses on oral drug-delivery techniques. Entrega is working on developing orally-available versions of several types of biologic drugs (a class that includes insulin and antibodies) that are made by Enlight’s pharmaceutical partners and typically require injection. Entrega will receive an undisclosed amount of upfront and research milestone payments from its partners. The company, whose scientific advisory board is chaired by biotech entrepreneur and MIT professor Robert Langer, said it will remain independent and retain all rights to its platform technology. Enlight Biosciences started in 2008 as a collaboration between Pfizer, Merck, Eli Lilly, and Boston-based PureTech Ventures. The firm has since forged partnerships with Johnson & Johnson, Novartis, and Abbott Laboratories.
By posting a comment, you agree to our terms and conditions.